Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Recruiting 6Terminated 5Unknown 4Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Breast Neoplasms 704Carcinoma, Non-Small-Cell Lung 470Prostatic Neoplasms 420Neoplasms 380Multiple Myeloma 264Colorectal Neoplasms 261Lung Neoplasms 247Neoplasm Metastasis 229Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 189Pancreatic Neoplasms 182Squamous Cell Carcinoma of Head and Neck 163Recurrence 147Carcinoma, Renal Cell 145Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 135Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Brain Neoplasms 124Carcinoma, Hepatocellular 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Immunologic Deficiency Syndromes × Clear all
NCT04554914 2026-04-27

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Pierre Fabre Medicament

Phase 2 Active not recruiting
190 enrolled
LymphoidSarcoma

Immunologic Deficiency Syndromes, Leiomyosarcoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡